Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 19, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 … Continued
Conference Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif., May 18, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 … Continued
Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies RANCHO CORDOVA, Calif., March 28, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial … Continued
Conference Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif., March 23, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 … Continued
ThermoGenesis Holdings had the pleasure of having our very own C.E.O., Dr. Chris Xu, featured in a Q&A article by BioPharm International where a panel of experts were asked questions about the growth, challenges & opportunities within the cell & gene therapy industry. We invite you to read the BioPharm international article which can be … Continued
Preparing cell samples is an essential part of achieving success in cell and gene therapy manufacturing. Achieving high-quality results requires that samples be pure, with high viability and free of any damage caused by harsh retrieval techniques. Current cell isolation techniques can be time-consuming and cause stress to cell samples, which is why there is … Continued
RANCHO CORDOVA, Calif., January 11, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to … Continued
RANCHO CORDOVA, Calif., January 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The … Continued
RANCHO CORDOVA, Calif., December 17, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum. A quorum consists of a majority … Continued